U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

INFORMATION DISCLOSURE	
STATEMENT BY APPLICANT	
(Not for submission under 37 CFR 1.99)	

 Application Number
 10531813

 Filing Date
 2005-04-18

 First Named Inventor
 Takashi Naka

 Art Unit
 NA

 Examiner Name
 NA VYEI Assigned

 Attomey Docket Number
 0088400202697-US0

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	late	of cited Document		Pages,Columns,Lines wher Relevant Passages or Relev Figures Appear			
	1										
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.	_	Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Cite Publication Number Kind Code1 Date				tion	Name of Pate of cited Docu	entee or Applicant ment	Releva		ines where es or Relev		
	1										
If you wish	h to a	dd additional U.S. Publi						d button	=		
				FOREIG	IN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	vhere Rele	r Relevant	T.
1	1	1171434	CN			1998-01-28	Nihon Parkerizing				×
2	2	1260825	CN			2000-07-19	Shell Internat Res I	ви			×
3	3	1057478	CN			1992-01-01	Xue Zhichun				×

U.S. PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10531813			
Filing Date		2005-04-18			
First Named Inventor Takas		shi Nakai			
Art Unit		N/A			
Examiner Name Not Y		et Assigned			
Attorney Docket Numb	er	09864/0202607-US0			

4	4	1170075	5	EP		2002-01-09		yota Chuo Kenkyusho et al.			
5	5	2152156	3	RU		2000-07-10	Kei	llogg Kompani			×
If you wish	h to a	dd additio	onal Foreign F	atent Docume	ent citation	information p	leas	e click the Add buttor	n Add		
				NON-PA	TENT LIT	RATURE DO	CUI	MENTS	Remove		
Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher. (in)							Тŝ		
	1										
If you wis	h to a	dd additio	onal non-pater	nt literature do	cument ci	tation informat	tion p	please click the Add I	outton Ad	ld	
EXAMINER SIGNATURE											
Examiner Signature Date Considered											
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											

1 See Knd. Codes of USPTO Plant Documents at year, USPTO, DOLY or MPEP 901.04. Feater office in the issued for document, by the two-leter code (WIPO) Standard 573.3. Feater office in the Engineer parts occuments, be included on the year of the reight of the Engineer parts proceed be set all number of the patent 500-cument. Feater office in the parts of t

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10531813		
Filing Date		2005-04-18		
First Named Inventor Takas		shi Nakar		
Art Unit		N/A		
Examiner Name Not Y		et Assigned		
Attorney Docket Number		09864/0202607-US0		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

l٢	Fee	set forth in	37 CFR	1.17 (p)	has been	submitted herewit	h.

Na.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/FB/ Flynn Barrison (53,970)	Date (YYYY-MM-DD)	2007-05-01
Name/Print	Louis J. DelJuidice	Registration Number	47522

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.